Trial Search Results

Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

B7451012 is a Phase 3 study to evaluate PF-04965842 in patients aged 12 years and older with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. The efficacy and safety of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily, will be evaluated relative to placebo over 12 weeks of study participation. Eligible patients will have an option to enter a long-term extension study after completing 12 weeks of treatment.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Pfizer

Stanford Investigator(s):

Intervention(s):

  • Drug: PF-04965842 100 mg
  • Drug: PF-04965842 200 mg
  • Drug: Placebo

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - 12 years of age or older with a minimum body weight of 40 kg

   - Diagnosis of atopic dermatitis (AD) for at least 1 year and current status of moderate
   to severe disease (>= the following scores: BSA 10%, IGA 3, EASI 16, Pruritus NRS 4)

   - Recent history of inadequate response or inability to tolerate topical AD treatments
   or require systemic treatments for AD control

Exclusion Criteria:

   - Unwilling to discontinue current AD medications prior to the study or require
   treatment with prohibited medications during the study

   - Prior treatment with JAK inhibitors

   - Other active nonAD inflammatory skin diseases or conditions affecting skin

   - Medical history including thrombocytopenia, coagulopathy or platelet dysfunction, Q
   wave interval abnormalities, current or history of certain infections, cancer,
   lymphoproliferative disorders and other medical conditions at the discretion of the
   investigator

   - Pregnant or breastfeeding women, or women of childbearing potential who are unwilling
   to use contraception

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Elidia V. Tafoya, MPH
650-724-1982
Recruiting